Substance / Medication

Oseltamivir phosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Design and evaluation of oseltamivir phosphate dual-phase extended-release tablets for the treatment of influenza.
Yu Liping, Huang Xin, Jiang Manhua et al. · Int J Pharm · 2024
PMID: 38914352RCT
Efficacy of oseltamivir phosphate to horses inoculated with equine influenza A virus.
Yamanaka Takashi, Tsujimura Koji, Kondo Takashi et al. · J Vet Med Sci · 2006
PMID: 17019060RCT
Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
Shin Jin Soo, Ku Keun Bon, Jang Yejin et al. · J Microbiol · 2017
PMID: 29214495Observational
Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study.
Kakeya Hiroshi, Seki Masafumi, Izumikawa Koichi et al. · PLoS One · 2014
PMID: 24632748ObservationalFull text (PMC)
Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan.
Ghosh Gopal C, Nakada Norihide, Yamashita Naoyuki et al. · Environ Health Perspect · 2010
PMID: 20056566ObservationalFull text (PMC)
Development and validation of a rapid capillary electrophoresis method for the determination of oseltamivir phosphate in Tamiflu and generic versions.
Laborde-Kummer Evelyne, Gaudin Karen, Joseph-Charles Julienne et al. · J Pharm Biomed Anal · 2009
PMID: 19540085Observational
An experience of oseltamivir phosphate (tamiflu™) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report.
Alioglu Bulent, Tasar Aysin, Ozen Cinar et al. · Pathophysiol Haemost Thromb · 2010
PMID: 21063076Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Oseltamivir phosphate (substance)
SNOMED CT
116113006
UMLS CUI
C0872908

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.